



A Themed Issue in Honor of Professor Jean-Francois Timsit— Outstanding Contributions in the Fields of Hospital-Acquired Infections and Optimization of Anti-infective Treatments

Guest Editor:

Prof. Dr. Vincent Jullien

Pharmacology – Hospital
Practitioner, Sorbonne Paris
Nord University Pharmacology
Unit, Paris Seine Saint-Denis
University Hospital, Bobigny,
France

Message from the Guest Editor

Professor Jean-François Timsit has significantly contributed to the field of infectious diseases in critically ill patients. His research covers a wide range of topics, including sepsis and antimicrobial therapy, catheter-related infections, ventilator-associated pneumonia, quality of care improvement, prognostic models, and competing risks.

Antibiotics is pleased to announce a Special Issue in recognition of Professor Jean-François Timsit's outstanding contributions to the knowledge of hospital-acquired infections and antimicrobial treatment. This Special Issue is dedicated to all aspects of sepsis and antimicrobials in ICU patients with an emphasis on the following topics (though others will be considered):

- Nosocomial infections;
- Ventilator-acquired pneumonia and hospital-acquired pneumonia;
- Catheter infections;
- Antimicrobial agents against multidrug-resistant pathogens;
- Antibiotic stewardship in ICU patients;
- Resistance emergence in ICU patients;
- Prognostic models in ICU patients;
- Pharmacokinetics and pharmacodynamics of antimicrobials in ICU patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)